Serum adipokine levels in the obese people by Tasci, Ilker et al.





I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2009; 5(3):286 
© Ivyspring International Publisher. All rights reserved 
Letter 
Serum adipokine levels in the obese people 
Ilker Tasci 
, Teoman Dogru, Gokhan Erdem, Serkan Tapan, Cemal Nuri Ercin, Alper Sonmez 
Gulhane School of Medicine, Department of Internal Medicine, Etlik 06018 Ankara, Turkey   

 Correspondence to: Professor Ilker Tasci, itasci@gata.edu.tr 
Published: 2009.04.03 
 
We read the article by Onat et al (1) on the asso-
ciation of serum adiponectin with obesity, hyperinsu-
linemia, lipoproteins, inflammatory markers and sex 
hormone binding globulin. In a relatively large 
population sample, they report some interesting re-
sults based mostly on statistical associations that, to 
our understanding, might not wholly represent the 
studied population itself. 
As we know, other than the body fat content, 
degree of insulin sensitivity and age, there are some 
more major determinants of circulating adiponectin. 
First, we clearly know that not only the people with 
diabetes mellitus but also those with impaired glucose 
tolerance have lower adiponectin level compared to 
healthy controls (2). Second, increased blood pressure 
is a condition with decreased adiponectin concentra-
tion (3,4). Third, as the authors noticed in their model, 
medications for metabolic diseases such as diabetes, 
hypertension or dyslipidemia significantly alter blood 
level of adipokines (5-7). 
The authors state in their paper that blood adi-
ponectin has no association with antidiabetic, anti-
hypertensive or hypolipidmic medications. However, 
no information was given about the fasting glucose 
level or glucose tolerance status of the other partici-
pants without documented diabetes most of whom 
were obese. Moreover, it appears that newly diag-
nosed or insufficiently treated diabetes or hyperten-
sion was categorized in the same group with estab-
lished disease, which needs to be argued further. 
Therefore, it would be appreciated if the authors 
could present some more data adjusted for major 
confounders including fasting glucose, prediabetes 
and newly diagnosed or untreated diabetes and hy-
pertension. This could provide the readers of the 
journal clearer information in relation to the link be-
tween adiposity, adipokines and insulin sensitivity. 
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